MDXHealth announced the peer-reviewed publication of the Oxford GPS-ProMPT study in the journal European Urology Oncology. The publication marks the first major peer-reviewed milestone from the collaboration with the University of Oxford. It serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study, which has the potential to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence in localized prostate cancer.

Michael K. McGarrity, Chief Executive Officer of mdxhealth, stated that the acceptance of Professor Freddie Hamdy’s GPS-ProMPT study is an important milestone. He noted that the findings provide the scientific foundation for the ongoing GPS-ProtecT study. McGarrity added that the publication supports the advancement of GPS regarding guideline development, payer coverage, and physician adoption.

Lead author Dr Nikita Sushentsev from Cambridge University Hospitals NHS Foundation of Trust commented on the findings. The ProMPT findings demonstrate that patients with favorable GPS mdx scores achieved excellent long-term outcomes. This includes 92% freedom-from-failure at six years in active surveillance and up to 100% in surgery and radiotherapy cohorts. These results were observed even among patients with adverse clinical risk factors.

The study suggests that GPS mdx can identify favorable tumor biology that traditional risk stratification alone would miss. This has meaningful implications for how physicians counsel patients facing treatment decisions. The publication is expected to influence future guideline development and payer coverage for genomic classifiers in prostate cancer.